-
Eli Lilly Launches Kisunla in China for Early Alzheimer’s Treatment
•
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has officially launched Kisunla (donanemab) in China, a Category 1 drug approved in December last year for treating early symptomatic Alzheimer’s disease (AD). This includes adults with mild cognitive impairment (MCI) and mild dementia stage AD. Therapy DetailsKisunla is administered as…
-
Zhejiang Funow Medicine Launches Triple Cream for Melasma Treatment in China
•
China-based Zhejiang Fonow Medicine Co., Ltd. (formerly known as: Zhejiang Rishengchang Pharmaceutical Co., Ltd.) has announced the official market launch of its fluocinolone acetonide, hydroquinone, and tretinoin cream in China for the treatment of melasma. This marks a significant advancement in the treatment landscape for this common pigmentation disorder. Innovative…
-
AstraZeneca Officially Launches Fasenra for Severe Eosinophilic Asthma in China
•
UK-based pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has announced the official market launch of its monoclonal antibody Fasenra (benralizumab) in China. The drug is approved as a maintenance therapy for severe eosinophilic asthma (SEA) in adults and adolescents aged 12 and above. Clinical Trial and ApprovalFasenra received marketing approval in…
-
GE Healthcare Unveils Invenia ABUS Premium for Enhanced Dense Breast Screening
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced the launch of the Invenia Automated Breast Ultrasound (ABUS) Premium. This advanced 3D ultrasound system integrates artificial intelligence (AI) and innovative features to enable faster, reproducible supplemental screening and streamline exam readings for patients with…
-
Daiichi Sankyo Launches Datroway in Japan for HR Positive, HER2 Negative Breast Cancer
•
Japan-based Daiichi Sankyo (TYO: 4568) has announced the launch of Datroway (datopotamab deruxtecan) in Japan. The drug is approved for treating adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer who have undergone prior chemotherapy. First TROP2-Directed Therapy…
-
Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai
•
China-based Trinomab Biotech Co., Ltd announced the first delivery of its antitetanus toxin monoclonal antibody (mAb) injection Xintituo (siltartoxatug) in Zhuhai, Guangdong province. This marks a significant advancement in the treatment and prevention of tetanus, offering a more efficient and safer alternative to traditional methods. Advantages Over Traditional ProductsTraditional horse…
-
Johnson & Johnson Officially Launches Spravato in China for Depression Treatment
•
US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in China to alleviate depressive symptoms in adult depression patients. The announcement comes after a swift approval by China’s National Medical Products Administration (NMPA) in April 2023. Spravato’s novel mechanism and rapid resultsSpravato is the first…
-
Bio-heart’s Iberis RDN System Completes First Commercial Surgery in Germany
•
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the successful completion of its first commercial surgery using the Iberis multi-electrode renal radiofrequency denervation (RDN) system in Germany. The procedure was performed by Dr. Saarraaken Kulenthiran at the University Hospital of Saarland, with no complications or adverse events reported.…
-
J&J MedTech Launches Locally Produced HARMONIC 7s Scalpel in China
•
Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC 7s ultrasonic scalpel instrument in China, marking a milestone with local production at its Suzhou plant. Product HighlightsThe HARMONIC 7s features an innovative built-in intelligent chip and proprietary next-generation adaptive tissue algorithm (ATT), enabling continuous…
-
Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing by expansion (SBX) technology, marking a significant advancement in next-generation sequencing (NGS). Technology OverviewSBX integrates innovative sensor modules to provide ultra-fast and high-throughput sequencing solutions. The technology is designed with broad flexibility and scalability, making…
-
Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China
•
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, announced the global launch of its efsubaglutide alfa, a next-generation ultra-long-acting glucagon-like peptide 1 (GLP-1) receptor agonist for the treatment of type 2 diabetes (T2D), in Changshu, Jiangsu province. Drug ProfileEfsubaglutide alfa, with an average half-life of…
-
Luye Pharma Launches Erzofri in US Market
•
China-based Luye Pharma Group (HKG: 2186) has announced the initiation of commercialization of its in-house developed Erzofri (paliperidone palmitate extended-release injectable suspension) in the United States, with the first batch of products already shipped. This marks a significant milestone in the company’s global expansion strategy. Erzofri: Long-Acting Injection for SchizophreniaErzofri…
-
Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative diabetes treatment, Rybelsus (semaglutide), in China. This marks a significant milestone for the company as it expands its presence in the Chinese market. Rybelsus: A First-in-Class TherapyRybelsus holds the distinction of being the world’s first…
-
GSK Launches Cabotegravir Injection in China for HIV Pre-Exposure Prophylaxis
•
UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection in China. The integrase strand transfer inhibitor (INSTI) was approved in May of last year for pre-exposure prophylaxis (PrEP) of HIV-1 in adults and adolescents (weighing ≥ 35kg) at risk of infection, to reduce the…
-
Eli Lilly & Co. Launches Mounjaro (Tirzepatide) in China for Diabetes and Weight Management
•
US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch of its drug Mounjaro (tirzepatide) in China, expanding access to this treatment for patients in the region. Coverage of Two IndicationsThe launch of Mounjaro in China covers two specific indications. The first is for the…
-
Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China
•
US-based medical device leader Boston Scientific Corporation (NYSE: BSX) has announced the market launch of its Athletis peripheral balloon dilatation catheter in mainland China. This product is designed for percutaneous transluminal angioplasty (PTA) of the peripheral vascular system and is utilized in the treatment of stenotic lesions in autologous or…
-
Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its sacituzumab tirumotecan (SKB264/MK-2870) in China, marking a significant milestone in the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have been previously treated with at least two…
-
Everest Medicines’ Nefecon Receives First Prescription for IgAN Treatment in Adults
•
China-based Everest Medicines (HKG: 1952) has announced that its targeted-release budesonide, Nefecon, has been prescribed for the first time to treat primary immunoglobulin A nephropathy (IgAN) in adults who are at risk of disease progression. This development signifies a significant step forward in the management of IgAN, a condition that…
-
Everest Medicines’ Velsipity (Etrasimod) Receives First Prescription in Foshan under GBA Policy
•
Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced that its Velsipity (etrasimod) has been prescribed for the first time at Foshan Fosun Chancheng Hospital. This prescription was made possible under the “Hong Kong-Macau Drug and Device Access” policy, which is part of the Greater Bay…
-
China Medical System’s Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use
•
China Medical System Holdings (CMS; HKG: 0867) has announced that the first prescriptions have been issued in China for its methylthioninium enteric coated sustained-release tablets. These tablets are designed to enhance the visualization of colorectal lesions in adult patients undergoing colonoscopy screening or monitoring. Methylthioninium’s Multi-Matrix Technology and MechanismMethylthioninium utilizes…
